Next Gen Pharma: Lower dose of H1N1 vaccine may be enough

With flu season hotting up, debate over the use of Influenza A (H1N1) vaccines continues to divide opinion. Now, Swiss-based pharmaceutical giant Novartis has announced that half of the currently-approved US dose actually fulfils immune response criteria for adults and the elderly.

Novatis' announcement is based on new interim data from ongoing clinical trials, and shows how a single 3.75µg dose of MF59-adjuvanted A(H1N1) 2009 vaccine met serologic protection criteria against influenza A(H1N1) in children ages three to eight, adults ages 18 to 64, and the elderly.

As such, the pharmaceutical firm is now in discussions with the US Food and Drug Administration (FDA) and is set to perfrom additional analysis suggested by the agency.

Read the rest of the article here:
Next Gen Pharma: Lower dose of H1N1 vaccine may be enough